© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Colorectal Cancer
The Science Leading to Robust Responses in MSI-High Mismatch Repair Deficient mCRC in CheckMate 142
July 23, 2020
In an interview with Targeted Oncology, Heinz-Josef Lenz, MD, PhD, discussed the history of immune checkpoint inhibition in the metastatic colorectal cancer treatment paradigm.
Analyzing the Importance of Biomarker Testing and MSI Status in mCRC
July 20, 2020
Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate-142 trial.
FDA Approves Frontline Pembrolizumab for MSI-H/dMMR CRC
June 29, 2020
"Patients with unresectable or metastatic MSI-H colorectal cancer have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options."
Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01
June 29, 2020
Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.
NDA Seeks Accelerated Approval of CPP-1X/sul for Familial Adenomatous Polyposis
June 29, 2020
A New Drug Application was submitted to the FDA seeking accelerated approval of eflornithine in combination with sulindac for the treatment of adult patients with familial adenomatous polyposis.
Fruquitinib Receives FDA Fast Track Designation for Metastatic Colorectal Cancer
June 18, 2020
Fruquitinib was granted Fast Track Designation for the treatment of patients with metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy, as well as anti-EGFR therapy for RAS wild-type tumors
Preventative Measures and Cancer Screening Recommendations Aid Male Population
June 17, 2020
"Cancer is now the number 1 cause of death in many parts of the United States and overall, men are at a 50% likelihood of having some sort of cancer diagnosed in their lifetime, where it is slightly lower in women at about a third."
Survey Identifies Trends and Unmet Needs for Young-Onset Colorectal Cancer
June 09, 2020
In an attempt to better understand the critical unmet needs of young survivors of and patients with colorectal cancer, the Colorectal Cancer Alliance launched an annual survey. These latest findings indicate the unique challenges of young-onset CRC and the need to continue improving this treatment landscape.
Early Data From Tilsotolimod Plus Nivolumab and Ipilimumab Leads to Expansion of MSS-CRC Trial
June 03, 2020
Tilsotolimod has demonstrated innate and adaptive immune activation in multiple tumors. Now, some safety and efficacy data have been reported for the combination of tilsotolimod plus nivolumab and ipilimumab.
Updated Survival Data from BEACON CRC Lead to More Specific Questions
June 02, 2020
Scott Kopetz, MD, PhD, discusses the next steps following the phase 3 BEACON CRC trial of encorafenib plus cetuximab with or without binimetinib compared with irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E metastatic colorectal cancer.